AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$RGEN

Loeillot Olivier sold $977K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Aug 21, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RGEN
Neutral
medium confidence
Mentioned
$RGEN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$RGENNeutralMedium confidence
Context

CEO Olivier Loeillot sold 5,426 shares for $976,680 via a 10b5‑1 plan, reducing his stake to 54,246 shares.

Expected impact

Potential minor downward pressure, likely within normal volatility range.

Evidence & confidence

The sale amount is under $1M and represents a small percentage of total holdings, limiting market impact.

Market effects

Sector

Minimal effect on biotech/healthcare sector; insider sales are routine.

Regional

No regional impact beyond investor perception of RGEN.

Global

Limited global relevance; only relevant to RGEN shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a bearish signal.

Key entities

  • Person
    Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

  • Company
    Repligen Corp

    Biopharmaceutical company listed on NASDAQ under ticker RGEN.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RGEN insider trading history →

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min